Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy (NCT05824520) | Clinical Trial Compass
RecruitingNot Applicable
Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy
China1,066 participantsStarted 2024-10-10
Plain-language summary
The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years, with at least one vessel has CT-derived FFR≤0.80
* Patients with chronic coronary syndromes
* Signed written informed consent
Exclusion Criteria:
* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media (Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled)
* Prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
* Sinus arrhythmia, cardiogenic shock, or severe heart failure (NYHA≥III)
* Inability or unwillingness to undergo CT scan or coronary angiography
* Patients on hemodialysis or with severe hepatic or renal insufficiency
* Left main coronary artery stenosis ≥ 50%
* Target vessel total occlusion
* Pregnancy or intention to become pregnant during the course of the trial
* Patients with a life expectancy less than 2 years
What they're measuring
1
Major adverse cardiac events (MACE)
Timeframe: 1 year
Trial details
NCT IDNCT05824520
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University